Rezolute completes Phase 2 DME enrollment, initiates Phase 3 for congenital hyperinsulinism

Rezolute, Inc.

Phase 2 study of oral RZ402 for diabetic macular edema enrolled ~95 participants; topline data expected mid-Q2 2024.
Phase 3 sunRIZE study of RZ358 for congenital hyperinsulinism initiated; first clinical site activated outside US.
Phase 3 to enroll up to 56 patients at ~20 centers in >12 countries; topline results anticipated mid-2025.
RZ358 previously received EMA PRIME designation in October 2023 for congenital hyperinsulinism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.